APP and Alzheimer disease: This thereby reduces the activation of NF-κB p65 protein, down-regulates the expression of COX-2, iNOS proteins and the expression of TNF-α, IL-1β, and IL-6 pro-inflammatory factors, thus alleviating the syndromes of AD in APP/PS1 mice.